Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (4956)	5/21/1998 1:54:00 AM
From: Vector1	Read Replies (1) \| Respond to of 9719

Harold, I pulled the following from a Paine Webber report on the convert . The report was issue today. <<We rate Genzyme attractive and based on a mid-20 multiple on our 1999 EPS estimate of $1.70, our 12-month target price range is $35- 40.>> I believe the consensus for the year is about $1.40. If Renagel gets approved there is significant upside to the $1.70 99 number. The market has totally discounted Seprafilm so there is upside there to. The risk is the continued weakness in the surgical business which was a mistake in the first place. Low margins and powerful competitors. In sum the downside is minimal and the upside is a 50% gain in 12 months. V1